Current and future theranostic applications of the lipid-calcium-phosphate nanoparticle platform

Theranostics

Volumn 6, Issue 7, 2016, Pages 918-929

  Satterlee, Andrew B ^a,b   Huang, Leaf ^a,b  

^a UNC Hamner Institute for Drug Safety Sciences   (United States)

^b Biomedical Research Imaging Center   (United States)

Author keywords

Cancer; LCP; Nanoparticle; PET; SIRT; SPECT; Theranostic

Indexed keywords

CESIUM 131; COPPER 64; DNA; FLUORODEOXYGLUCOSE F 18; GADOLINIUM CHELATE; GALLIUM 68; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 123; IODINE 125; LIPID CALCIUM PHOSPHATE NANOPARTICLE; LUTETIUM 177; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OCTREOTIDE; PALLADIUM 103; SMALL INTERFERING RNA; TECHNETIUM 99M; UNCLASSIFIED DRUG; YTTRIUM 90; CALCIUM PHOSPHATE; LIPID; RADIOISOTOPE;

BRACHYTHERAPY; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; HUMAN; LIVER CELL CARCINOMA; METASTATIC COLORECTAL CANCER; NEOPLASM; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE; RADIOIMMUNOTHERAPY; RADIOISOTOPE DECAY; REVIEW; SELECTIVE INTERNAL RADIATION THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERANOSTIC NANOMEDICINE; PROCEDURES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; TRENDS;

CALCIUM PHOSPHATES; HUMANS; LIPIDS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY COMPUTED TOMOGRAPHY; THERANOSTIC NANOMEDICINE;

EID: 84979596914     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.14689     Document Type: Review

References (83)

1. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010;62(11): 1064-79.
2. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. Mol Pharm 2011;8(6): 2101-41.
3. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973;52(2): 456-67.
4. Maitra A. Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy. Expert Rev Mol Diagn 2005;5(6): 893-905.
5. Sokolova VV, Radtke I, Heumann R, Epple M. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials 2006;27(16): 3147-53.
6. Liu T, Tang A, Zhang G, et al. Calcium phosphate nanoparticles as a novel nonviral vector for efficient transfection of DNA in cancer gene therapy. Cancer Biother Radiopharm 2005;20(2): 141-9.
7. Li J, Chen YC, Tseng YC, Mozumdar S, Huang L. Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery. J Control Release 2010;142(3): 416-21.
8. Li J, Yang Y, Huang L. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor. J Control Release 2012;158(1): 108-14.
9. Giger EV, Puigmarti-Luis J, Schlatter R, Castagner B, Dittrich PS, Leroux JC. Gene delivery with bisphosphonate-stabilized calcium phosphate nanoparticles. J Control Release 2011;150(1): 87-93.
10. Lee MS, Lee JE, Byun E, et al. Target-specific delivery of siRNA by stabilized calcium phosphate nanoparticles using dopa-hyaluronic acid conjugate. Journal of Controlled Release 2014;192: 122-30.
11. Chen WH, Lecaros RL, Tseng YC, Huang L, Hsu YC. Nanoparticle delivery of HIF1alpha siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Lett 2015;359(1): 65-74.
12. Tang J, Li L, Howard CB, Mahler SM, Huang L, Xu ZP. Preparation of optimized lipid-coated calcium phosphate nanoparticles for enhanced in vitro gene delivery to breast cancer cells. Journal of Materials Chemistry B 2015;3(33): 6805-12.
13. Jung H, Kim SA, Yang YG, Yoo H, Lim SJ, Mok H. Long chain microRNA conjugates in calcium phosphate nanoparticles for efficient formulation and delivery. Arch Pharm Res 2015;38(5): 705-15.
14. Au KM, Satterlee A, Min Y, et al. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic. Biomaterials 2016;82: 178-93.
15. Zhang J, Miao L, Guo S, et al. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model. J Control Release 2014;182: 90-6.
16. Zhang Y, Kim WY, Huang L. Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy. Biomaterials 2013;34(13): 3447-58.
17. Yao J, Zhang Y, Ramishetti S, Wang Y, Huang L. Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate. J Control Release 2013;170(3): 414-20.
18. Xu Z, Wang Y, Zhang L, Huang L. Nanoparticle-delivered transforming growth factor-beta siRNA enhances vaccination against advanced melanoma by modifying tumor microenvironment. ACS Nano 2014;8(4): 3636-45.
19. Zhang Y, Schwerbrock NM, Rogers AB, Kim WY, Huang L. Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC. Mol Ther 2013;21(8): 1559-69.
20. Zhang Y, Peng L, Mumper RJ, Huang L. Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy. Biomaterials 2013;34(33): 8459-68.
21. Yang Y, Li J, Liu F, Huang L. Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis. Mol Ther 2012;20(3): 609-15.
22. Yang Y, Hu Y, Wang Y, Li J, Liu F, Huang L. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm 2012;9(8): 2280-9.
23. Hu Y, Haynes MT, Wang Y, Liu F, Huang L. A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo. ACS Nano 2013;7(6): 5376-84.
24. Xu Z, Ramishetti S, Tseng YC, Guo S, Wang Y, Huang L. Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis. J Control Release 2013;172(1): 259-65.
25. Satterlee AB, Yuan H, Huang L. A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging. J Control Release 2015;217: 170-82.
26. Tseng YC, Xu Z, Guley K, Yuan H, Huang L. Lipid-calcium phosphate nanoparticles for delivery to the lymphatic system and SPECT/CT imaging of lymph node metastases. Biomaterials 2014;35(16): 4688-98.
27. Guo ST, Miao L, Wang YH, Huang L. Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. Journal of Controlled Release 2014;174: 137-42.
28. Guo S, Wang Y, Miao L, et al. Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano 2013;7(11): 9896-904.
29. Liu Y, Hu Y, Huang L. Influence of polyethylene glycol density and surface lipid on pharmacokinetics and biodistribution of lipid-calcium-phosphate nanoparticles. Biomaterials 2014;35(9): 3027-34.
30. Tseng YC, Yang A, Huang L. How Does the Cell Overcome LCP Nanoparticle-Induced Calcium Toxicity? Mol Pharm 2013;10(11): 4391-95.
31. Khalil MM, Tremoleda JL, Bayomy TB, Gsell W. Molecular SPECT Imaging: An Overview. Int J Mol Imaging 2011;2011: 796025.
32. Lu Z-R. Modern Pharmaceutics, Ch 6: In Vivo Imaging of Dosage Forms. 5 ed. New York: Informa Healthcare, 2009.
33. Van Audenhaege K, Van Holen R, Vandenberghe S, Vanhove C, Metzler SD, Moore SC. Review of SPECT collimator selection, optimization, and fabrication for clinical and preclinical imaging. Med Phys 2015;42(8): 4796-813.
34. Karp JS, Surti S, Daube-Witherspoon ME, Muehllehner G. Benefit of time-of-flight in PET: experimental and clinical results. J Nucl Med 2008;49(3): 462-70.
35. Banerjee SR, Pomper MG. Clinical applications of Gallium-68. Appl Radiat Isot 2013;76: 2-13.
36. McCarthy DW, Shefer RE, Klinkowstein RE, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 1997;24(1): 35-43.
37. Bednarczyk EM. Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, 3rd Edition. Ann Pharmacother 2012.
38. Khalil M. Basic Sciences of Nuclear Medicine. Springer, 2011.
39. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev 2010;110(5): 2858-902.
40. Bartholoma MD. Recent developments in the design of bifunctional chelators for metal-based radiopharmaceuticals used in Positron Emission Tomography. Inorganica Chimica Acta 2012;389: 36-51.
41. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des 2007;13(1): 3-16.
42. Pandya DN, Bhatt N, Dale AV, et al. New bifunctional chelator for 64Cu-immuno-positron emission tomography. Bioconjug Chem 2013;24(8): 1356-66.
43. Dale AV, An GI, Pandya DN, et al. Synthesis and Evaluation of New Generation Cross-Bridged Bifunctional Chelator for (64)Cu Radiotracers. Inorg Chem 2015;54(17): 8177-86.
44. Woodin KS, Heroux KJ, Boswell CA, et al. Kinetic inertness and electrochemical behavior of copper(II) tetraazamacrocyclic complexes: Possible implications for in vivo stability. European Journal of Inorganic Chemistry 2005;23: 4829-33.
45. Wilczek B, Svensson L, Danielsson R, Celebiouglu F, Larsson SA, Jacobsson H. 99mTc-exametazime as a breast tumor-seeking agent: comparison with 99mTc-sestamibi. J Nucl Med 2004;45(12): 2040-4.
46. Belhocine TZ, Blankenberg FG, Kartachova MS, et al. (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging 2015;42(13): 2083-97.
47. Rizvi T, Deng C, Rehm PK. Indium-111 Capromab Pendetide (ProstaScint((R))) Demonstrates Renal Cell Carcinoma and Aortocaval Nodal Metastases from Prostate Adenocarcinoma. World J Nucl Med 2015;14(3): 209-11.
48. Seymour LW, Ferry DR, Kerr DJ, et al. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 2009;34(6): 1629-36.
49. Pimm MV, Perkins AC, Strohalm J, Ulbrich K, Duncan R. Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J Drug Target 1996;3(5): 385-90.
50. Grillo-Lopez AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2002;2(5): 485-93.
51. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol 2011;24(2): 203-16.
52. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115(4): 807-11.
53. Kulkarni HS, Kasi PM. Rituximab and cytokine release syndrome. Case Rep Oncol 2012;5(1): 134-41.
54. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26(13): 2124-30.
55. Garske U, Sandstrom M, Johansson S, et al. Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma. Theranostics 2012;2(5): 459-71.
56. Delpassand ES, Samarghandi A, Zamanian S, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas 2014;43(4): 518-25.
57. Sandstrom M, Garske-Roman U, Granberg D, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med 2013;54(1): 33-41.
58. Di Pasqua AJ, Yuan H, Chung Y, et al. Neutron-activatable holmium-containing mesoporous silica nanoparticles as a potential radionuclide therapeutic agent for ovarian cancer. J Nucl Med 2013;54(1): 111-6.
59. Sadauskas E, Wallin H, Stoltenberg M, et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol 2007;4: 10.
60. Challapalli A, Jones E, Harvey C, Hellawell GO, Mangar SA. High dose rate prostate brachytherapy: an overview of the rationale, experience and emerging applications in the treatment of prostate cancer. Br J Radiol 2012;85 (Spec No 1): S18-27.
61. Yaparpalvi R, Rossinow J, Cavanagh WA, et al. Is Cs-131 or I-125 or Pd-103 the "Ideal" isotope for prostate boost brachytherapy? A dosimetric view point. International Journal of Radiation Oncology Biology Physics 2007;69(3): S677-S78.
62. Reed DR, Wallner KE, Merrick GS, et al. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy 2007;6(2): 129-34.
63. Yu Y, Anderson LL, Li Z, et al. Permanent prostate seed implant brachytherapy: report of the American Association of Physicists in Medicine Task Group No. 64. Med Phys 1999;26(10): 2054-76.
64. Khan MK, Minc LD, Nigavekar SS, et al. Fabrication of (Au-198(0)) radioactive composite nanodevices and their use for nanobrachytherapy. Nanomedicine-Nanotechnology Biology and Medicine 2008;4(1): 57-69.
65. Gulec SA, Pennington K, Wheeler J, et al. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial. Am J Clin Oncol 2013;36(5): 455-60.
66. Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer 2014;14: 897.
67. Ren Y, Mu Y, Song Y, et al. A new peptide ligand for colon cancer targeted delivery of micelles. Drug Deliv 2015: 1-10.
68. Zhang J, Gao J, Tan X, Wang M, Qin R. Effects of down-regulation of integrin-beta1 expression on migration and hepatic metastasis of human colon carcinoma. J Huazhong Univ Sci Technolog Med Sci 2010;30(4): 464-9.
69. Filmus J, Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 2013;280(10): 2471-6.
70. Lee YL, Ahn BC, Lee Y, Lee SW, Cho JY, Lee J. Targeting of hepatocellular carcinoma with glypican-3-targeting peptide ligand. J Pept Sci 2011;17(11): 763-9.
71. Roberts EA, Sarkar B. Liver as a key organ in the supply, storage, and excretion of copper. Am J Clin Nutr 2008;88(3): 851S-4S.
72. Ferrari C, Asabella AN, Villano C, et al. Copper-64 Dichloride as Theranostic Agent for Glioblastoma Multiforme: A Preclinical Study. Biomed Research International 2015.
73. Hellman NE, Gitlin JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002;22: 439-58.
74. Pandya DN, Kim JY, Park JC, et al. Revival of TE2A; a better chelate for Cu(II) ions than TETA? Chem Commun (Camb) 2010;46(20): 3517-9.
75. Garrison JC, Rold TL, Sieckman GL, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using Cu-64 bombesin analogs: Side-by-side comparison of the CB-TE2A and DOTA chelation systems. Journal of Nuclear Medicine 2007;48(8): 1327-37.
76. Liu S, Li D, Huang CW, et al. The efficient synthesis and biological evaluation of novel bi-functionalized sarcophagine for (64)cu radiopharmaceuticals. Theranostics 2012;2(6): 589-96.
77. Gourni E, Del Pozzo L, Kheirallah E, et al. Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer. Mol Pharm 2015;12(8): 2781-90.
78. Edelman RR, Warach S. Magnetic resonance imaging (1). N Engl J Med 1993;328(10): 708-16.
79. Fries PaB, Elie. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging. West Sussex, United Kingdom: Wiley, 2013.
80. Carr DH, Brown J, Bydder GM, et al. Intravenous Chelated Gadolinium as a Contrast Agent in Nmr Imaging of Cerebral-Tumors. Lancet 1984;1(8375): 484-86.
81. Jenjob R, Kun N, Ghee JY, et al. Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent. Mater Sci Eng C Mater Biol Appl 2016;61: 659-64.
82. Liu Y, Tseng YC, Huang L. Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method? Pharm Res 2012;29(12): 3273-7.
83. Masilamani V, et al. Cancer diagnosis by autofluorescence of blood components. Journal of Luminescence 2004;109: 143-54.